T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOCS
1201
DELISTED
Focus Financial Partners Inc. Class A
FOCS
| $18.1M | ﹤0.01% |
664,544
+102,420
| +18% | +$3.34M |
|
1202
Liberty Broadband Class A
LBRDA
$5.2B
| $18.1M | ﹤0.01% |
175,928
-4,215
| -2% | -$414K |
|
1203
IPG Photonics
IPGP
$3.64B
| $18.1M | ﹤0.01% |
117,120
+900
| +0.8% | +$136K |
|
1204
Integer Holdings
ITGR
$4.25B
| $18M | ﹤0.01% |
214,759
-265,534
| -55% | -$19.9M |
|
1205
Match Group
MTCH
$8.42B
| $18M | ﹤0.01% |
267,131
-37,414
| -12% | -$2.45M |
|
1206
Adient
ADNT
$1.51B
| $17.8M | ﹤0.01% |
732,594
-1,373,801
| -65% | -$28.3M |
|
1207
Sportsman's Warehouse
SPWH
$47.2M
| $17.8M | ﹤0.01% |
4,701,475
+16,700
| +0.4% | +$71.1K |
|
|
APLS
1208
DELISTED
Apellis Pharmaceuticals
APLS
| $17.7M | ﹤0.01% |
699,212
+19,324
| +3% | +$393K |
|
1209
PVH
PVH
$3.77B
| $17.6M | ﹤0.01% |
186,196
-7,261
| -4% | -$803K |
|
1210
Rocket Pharmaceuticals
RCKT
$368M
| $17.6M | ﹤0.01% |
1,172,946
+232,542
| +25% | +$4.06M |
|
1211
Pacira BioSciences
PCRX
$931M
| $17.6M | ﹤0.01% |
404,373
+37,443
| +10% | +$1.59M |
|
|
CRAY
1212
DELISTED
Cray, Inc.
CRAY
| $17.4M | ﹤0.01% |
500,893
-2,038,631
| -80% | -$63.1M |
|
1213
NRG Energy
NRG
$25.3B
| $17.4M | ﹤0.01% |
496,088
-48,117
| -9% | -$1.81M |
|
1214
Globe Life
GL
$14.1B
| $17.4M | ﹤0.01% |
194,615
-12,739
| -6% | -$1.11M |
|
1215
Tandem Diabetes Care
TNDM
$1.62B
| $17.4M | ﹤0.01% |
268,911
+20,198
| +8% | +$1.3M |
|
1216
AdvanSix
ASIX
$444M
| $17.3M | ﹤0.01% |
708,754
-6,003
| -0.8% | -$168K |
|
|
GCP
1217
DELISTED
GCP Applied Technologies Inc.
GCP
| $17.1M | ﹤0.01% |
757,522
-1,552,695
| -67% | -$41.9M |
|
|
AVLR
1218
DELISTED
Avalara, Inc.
AVLR
| $17.1M | ﹤0.01% |
237,349
-318,061
| -57% | -$20.5M |
|
|
YMAB
1219
DELISTED
Y-mAbs Therapeutics
YMAB
| $17.1M | ﹤0.01% |
748,351
+108,054
| +17% | +$2.48M |
|
1220
Worthington Enterprises
WOR
$2.82B
| $17M | ﹤0.01% |
686,842
-9,601
| -1% | -$225K |
|
1221
Steel Dynamics
STLD
$37.6B
| $17M | ﹤0.01% |
563,977
-260,709
| -32% | -$7.97M |
|
|
TECD
1222
DELISTED
Tech Data Corp
TECD
| $17M | ﹤0.01% |
162,517
-11,582
| -7% | -$1.18M |
|
|
LDL
1223
DELISTED
Lydall, Inc.
LDL
| $16.8M | ﹤0.01% |
832,523
-428,753
| -34% | -$9.33M |
|
1224
CareDx
CDNA
$2.41B
| $16.8M | ﹤0.01% |
466,218
+60,500
| +15% | +$1.94M |
|
1225
Lamb Weston
LW
$7.43B
| $16.6M | ﹤0.01% |
262,157
+1,423
| +0.5% | +$93.9K |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.